nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfisoxazole—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.121	0.126	CbGbCtD
Sulfisoxazole—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.113	0.118	CbGbCtD
Sulfisoxazole—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.113	0.118	CbGbCtD
Sulfisoxazole—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.102	0.107	CbGbCtD
Sulfisoxazole—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.102	0.107	CbGbCtD
Sulfisoxazole—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0885	0.0925	CbGbCtD
Sulfisoxazole—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0859	0.0898	CbGbCtD
Sulfisoxazole—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0777	0.0812	CbGbCtD
Sulfisoxazole—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0777	0.0812	CbGbCtD
Sulfisoxazole—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0745	0.0779	CbGbCtD
Sulfisoxazole—EDNRA—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00307	0.0774	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.0026	0.0656	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00239	0.0601	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00172	0.0433	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00161	0.0407	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0016	0.0403	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00145	0.0364	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00131	0.0329	CbGpPWpGaD
Sulfisoxazole—Sulfamethazine—ALB—acquired immunodeficiency syndrome	0.00124	0.316	CrCbGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00122	0.0307	CbGpPWpGaD
Sulfisoxazole—Sulfamerazine—ALB—acquired immunodeficiency syndrome	0.00121	0.309	CrCbGaD
Sulfisoxazole—EDNRA—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00111	0.0279	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000969	0.0244	CbGpPWpGaD
Sulfisoxazole—Sulfamethizole—ALB—acquired immunodeficiency syndrome	0.000939	0.24	CrCbGaD
Sulfisoxazole—EDNRA—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000938	0.0236	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000893	0.0225	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000877	0.0221	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000808	0.0203	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000759	0.0191	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000759	0.0191	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000738	0.0186	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000668	0.0168	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000632	0.0159	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000625	0.0158	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000599	0.0151	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000594	0.015	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000578	0.0146	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000542	0.0136	CbGpPWpGaD
Sulfisoxazole—Sulfamethoxazole—ALB—acquired immunodeficiency syndrome	0.000527	0.135	CrCbGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00052	0.0131	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000509	0.0128	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000509	0.0128	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000456	0.0115	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000412	0.0104	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000407	0.0103	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000388	0.00977	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000388	0.00977	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000387	0.00976	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000379	0.00955	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000369	0.00931	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000349	0.0088	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000343	0.00863	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000295	0.00743	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000266	0.0067	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000234	0.0059	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000233	0.00587	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000224	0.00564	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000224	0.00564	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000219	0.00552	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000219	0.00552	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000212	0.00533	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000202	0.0051	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000199	0.00502	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000199	0.00502	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000167	0.0042	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000164	0.00414	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000162	0.00408	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.00016	0.00403	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000151	0.00382	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00015	0.00379	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000149	0.00376	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000138	0.00348	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000136	0.00344	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000125	0.00315	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000118	0.00296	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000118	0.00296	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.94e-05	0.00225	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.81e-05	0.00222	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.68e-05	0.00219	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	8.47e-05	0.00213	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.06e-05	0.00203	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.88e-05	0.00199	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	7.2e-05	0.00182	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.66e-05	0.00117	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.63e-05	0.00117	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.32e-05	0.000836	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.74e-05	0.00069	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.48e-05	0.000372	CbGpPWpGaD
